CoChat

BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion

Open access

The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index; 23 of the 60 sources its claims cite were checked for support.

Abstract

Abstract B- and T-lymphocyte attenuator (BTLA) levels are increased in patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF). This condition is characterized by susceptibility to infection and T-cell immune exhaustion. However, whether BTLA can induce T-cell immune exhaustion and increase the risk of infection remains unclear. Here, we report that BTLA levels are significantly increased in the circulating and intrahepatic CD4 + T cells from patients with HBV-ACLF, and are positively correlated with disease severity, prognosis, and infection complications. BTLA levels were upregulated by the IL-6 and TNF signaling pathways. Antibody crosslinking of BTLA activated the PI3K-Akt pathway to inhibit the activation, proliferation, and cytokine production of CD4 + T cells while promoting their apoptosis. In contrast, BTLA knockdown promoted their activation and proliferation. BTLA -/- ACLF mice exhibited increased cytokine secretion, and reduced mortality and bacterial burden. The administration of a neutralizing anti-BTLA antibody reduced Klebsiella pneumoniae load and mortality in mice with ACLF. These data may help elucidate HBV-ACLF pathogenesis and aid in identifying novel drug targets.

Overview

CoChat Summary

TL;DR

BTLA is upregulated on circulating and liver-infiltrating CD4+ T cells in HBV-ACLF and is linked to disease severity, infection, and poor prognosis. The paper shows that BTLA drives CD4+ T-cell exhaustion, and that genetic or antibody-mediated BTLA blockade improves immune function and reduces bacterial burden and mortality in mouse models.

Key findings

  • In HBV-ACLF patients, BTLA expression on peripheral blood CD4+ T cells was significantly increased, and it was also increased on liver-infiltrating CD4+ T cells; BTLA levels on CD4+ T cells were positively correlated with Child-Pugh, MELD, CLIF-SOFA, CLIF-C ACLFs, and COSSH-ACLF scores.
  • The discussion reports that 61.39% of HBV-ACLF patients developed bacterial infections during hospitalization, and the Results state that BTLA expression was higher in co-infected patients than in non-infected patients.
  • In patient samples, BTLA-high CD4+ T cells showed an exhausted phenotype: BTLA crosslinking suppressed CD25, CD38, and CD69, reduced IFN-γ, IL-2, and TNF-α production, reduced proliferation, and promoted apoptosis; BTLA shRNA reversed these effects.
  • In mouse ACLF models, BTLA-/- mice had higher CD4+ T-cell cytokine output and lower mortality/bacterial burden; a neutralizing anti-BTLA antibody reduced Klebsiella pneumoniae load and mortality, and in the ConA+CLP sepsis model BTLA-/- mice had lower mortality and bacterial DNA in blood.

Methods

  • Human study: blood from 104 CHB patients, 101 patients with severe liver injury, and 90 healthy controls; liver tissue from 5 hemangioma, 5 CHB, and 7 HBV-ACLF patients; among the severe liver injury group, 71 were HBV-ACLF.
  • Main assays: flow cytometry and immunofluorescence for BTLA/HVEM expression, cytokine measurements, shRNA knockdown and agonistic anti-BTLA crosslinking in CD4+ T cells, RNA-seq, RT-PCR, and western blotting for pathway analysis.
  • Animal work: WT and BTLA-/- C57BL/6 mice were used in ConA-induced ACLF, CCl4-induced ACLF, and CLP/K. pneumoniae infection models; outcomes included cytokines, bacterial load, pathology, and survival.

Limitations

  • Not stated in the paper.
  • Evident from the text: the mechanistic pathway work is based largely on ex vivo cell assays and mouse models, so direct causal confirmation in patients is not shown.
  • Evident from the text: some cohorts are relatively small for tissue analyses (e.g., 5 hemangioma, 5 CHB, 7 HBV-ACLF liver samples), which may limit generalizability.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41467-024-46047-8

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 BTLA expression was significantly increased on circulating and intrahepatic CD4+ T cells in patients with HBV-ACLF and was positively correlated with prognosis and infectious complications. a Flow cytometry diagram of BTLA expression on peripheral blood CD4+ T and CD8+ T cells in NC, CHB, and HBV-ACLF patients. Patients with HBV-ACLF had significantly increased expression of BTLA on peripheral blood CD4+ T cells (b, NC: n = 90 donors, CHB: n = 104 donors, HBV-ACLF: n = 71 donors) and intrahepatic CD4+ T cells (c, NC: n = 5 donors, CHB: n = 5 donors, HBV-ACLF: n = 7 donors) compared to NC and CHB patients, while there was no significant difference in the BTLA expression on CD8+ T cells from PBMC or from liver-infiltrating lymphocytes. d T-distributed stochastic neighbor embedding (t-SNE) was used to illustrate the increased expression of HVEM on CD80/CD86+ dendritic cells in patients with HBV-ACLF. e The mean fluorescence intensity (MFI) of BTLA expression on CD4+ T cells was positively correlated with the severity of the disease (Child-Pugh, MELD scores, CLIF-SOFA, CLIF-C ACLFs, and COSSH-ACLFs, n = 71 donors). f Changes in the MFI of CD4+BTLA+ T cells in the progression of HBV-ACLF (n = 71 donors). The MFI of CD4+BTLA+ T cells was increased in the coinfection patients (g, n = 44 donors) and poor prognosis group (h, left, n = 39 donors) compared with that in non-infected patients (n = 27 donors) and in those with good prognosis (n = 32 donors), respectively. h right HBV-ACLF patients with good prognosis (n = 9 donors), but not those with poor prognosis (n = 11 donors), had a significantly decreased MFI of CD4+BTLA+ T cells after 4 weeks of treatment. Data were calculated as mean ± SEM (b, c, f, g, h), Kruskal-Wallis H test followed by Dunn’s multiple comparison test (b, c, f), Mann–Whitney U test (g, h left) and Wilcoxon test (h, right). A two-sided P < 0.05 was considered significant.
Fig. 1 BTLA expression was significantly increased on circulating and intrahepatic CD4+ T cells in patients with HBV-ACLF and was positively correlated with prognosis and infectious complications. a Flow cytometry diagram of BTLA expression on peripheral blood CD4+ T and CD8+ T cells in NC, CHB, and HBV-ACLF patients. Patients with HBV-ACLF had significantly increased expression of BTLA on peripheral blood CD4+ T cells (b, NC: n = 90 donors, CHB: n = 104 donors, HBV-ACLF: n = 71 donors) and intrahepatic CD4+ T cells (c, NC: n = 5 donors, CHB: n = 5 donors, HBV-ACLF: n = 7 donors) compared to NC and CHB patients, while there was no significant difference in the BTLA expression on CD8+ T cells from PBMC or from liver-infiltrating lymphocytes. d T-distributed stochastic neighbor embedding (t-SNE) was used to illustrate the increased expression of HVEM on CD80/CD86+ dendritic cells in patients with HBV-ACLF. e The mean fluorescence intensity (MFI) of BTLA expression on CD4+ T cells was positively correlated with the severity of the disease (Child-Pugh, MELD scores, CLIF-SOFA, CLIF-C ACLFs, and COSSH-ACLFs, n = 71 donors). f Changes in the MFI of CD4+BTLA+ T cells in the progression of HBV-ACLF (n = 71 donors). The MFI of CD4+BTLA+ T cells was increased in the coinfection patients (g, n = 44 donors) and poor prognosis group (h, left, n = 39 donors) compared with that in non-infected patients (n = 27 donors) and in those with good prognosis (n = 32 donors), respectively. h right HBV-ACLF patients with good prognosis (n = 9 donors), but not those with poor prognosis (n = 11 donors), had a significantly decreased MFI of CD4+BTLA+ T cells after 4 weeks of treatment. Data were calculated as mean ± SEM (b, c, f, g, h), Kruskal-Wallis H test followed by Dunn’s multiple comparison test (b, c, f), Mann–Whitney U test (g, h left) and Wilcoxon test (h, right). A two-sided P < 0.05 was considered significant.CC BY · PubMed Central
Fig. 2 Phenotypic characteristics of BTLA+CD4+ T cells. a Flow cytometry was used to sort different BTLA subpopulations, followed by RNA-seq. b Differently expressed genes (DEGs) between BTLA+CD4+ T-cell subsets and BTLA-CD4+ T-cell subsets (all n = 2 donors). c Validation of DEGs in BTLA+CD4+ T-cell subsets and BTLA-CD4+ T-cell subsets in NC (n = 38 donors), CHB (n = 94 donors) and HBV-ACLF patients (n = 35 donors). d Representative flow cytometry of BTLA+CD4+ T-cell subsets and BTLA-CD4+ T-cell subsets. e Differentiation phenotypes of BTLA+ CD4+ T cells in NC (n = 26 donors), CHB (n = 17 donors), and HBV-ACLF patients (n = 13 donors). Compared with BTLA-CD4+T cells, BTLA+CD4+T cells secreted higher levels of IFN-γ, IL-2, and TNF-α (f, n = 10 donors), and showed a greater proliferation ability (g, n = 10 donors). Data were calculated as mean ± SEM (c), Two-way ANOVA followed by Sidak’s multiple-comparison test (c), Mann–Whitney test (e), and Wilcoxon test (f, g). A two-sided P < 0.05 was considered significant.
Fig. 2 Phenotypic characteristics of BTLA+CD4+ T cells. a Flow cytometry was used to sort different BTLA subpopulations, followed by RNA-seq. b Differently expressed genes (DEGs) between BTLA+CD4+ T-cell subsets and BTLA-CD4+ T-cell subsets (all n = 2 donors). c Validation of DEGs in BTLA+CD4+ T-cell subsets and BTLA-CD4+ T-cell subsets in NC (n = 38 donors), CHB (n = 94 donors) and HBV-ACLF patients (n = 35 donors). d Representative flow cytometry of BTLA+CD4+ T-cell subsets and BTLA-CD4+ T-cell subsets. e Differentiation phenotypes of BTLA+ CD4+ T cells in NC (n = 26 donors), CHB (n = 17 donors), and HBV-ACLF patients (n = 13 donors). Compared with BTLA-CD4+T cells, BTLA+CD4+T cells secreted higher levels of IFN-γ, IL-2, and TNF-α (f, n = 10 donors), and showed a greater proliferation ability (g, n = 10 donors). Data were calculated as mean ± SEM (c), Two-way ANOVA followed by Sidak’s multiple-comparison test (c), Mann–Whitney test (e), and Wilcoxon test (f, g). A two-sided P < 0.05 was considered significant.CC BY · PubMed Central
Fig. 3 Elevated BTLA expression on CD4+ T cells was induced by circulating inflammation cytokines in HBV-ACLF. a The levels of pro-inflammatory cytokines (IL-1β, IL-6, IL-22, and TNF-α) and anti-inflammatory cytokines (IL-10 and IL-37) were markedly increased in HBV-ACLF patients (n = 29 donors) compared with those in NC (n = 21 donors) and CHB patients (n = 53 donors). b Only rhIL-6 and rhTNF-α significantly increased BTLA expression on CD4+ T cells in a dose-dependent manner (n = 4 donors). c Comprehensive treatment (n = 9 donors) decreased the levels of IL-6 and TNF-α, as well as BTLA expression on CD4+ T cells. d Exposure of purified CD4+ T cells from NC to HBV-ACLF plasma (n = 13 donors) resulted in a higher BTLA expression on CD4+ T cells compared with exposure of PBMC to NC plasma, while HBV-ACLF plasma combined with anti-IL-6 and/or anti-TNF-α resulted in decreased BTLA expression on CD4+ T cells. Data were calculated as mean ± SEM (a, b, d), Kruskal-Wallis H test followed by Dunn’s multiple comparison test (a), Wilcoxon test (c), and one-way ANOVA followed by Tukey’s (b) or Dunnett’s multiple comparison test (d). A two-sided P < 0.05 was considered significant.
Fig. 3 Elevated BTLA expression on CD4+ T cells was induced by circulating inflammation cytokines in HBV-ACLF. a The levels of pro-inflammatory cytokines (IL-1β, IL-6, IL-22, and TNF-α) and anti-inflammatory cytokines (IL-10 and IL-37) were markedly increased in HBV-ACLF patients (n = 29 donors) compared with those in NC (n = 21 donors) and CHB patients (n = 53 donors). b Only rhIL-6 and rhTNF-α significantly increased BTLA expression on CD4+ T cells in a dose-dependent manner (n = 4 donors). c Comprehensive treatment (n = 9 donors) decreased the levels of IL-6 and TNF-α, as well as BTLA expression on CD4+ T cells. d Exposure of purified CD4+ T cells from NC to HBV-ACLF plasma (n = 13 donors) resulted in a higher BTLA expression on CD4+ T cells compared with exposure of PBMC to NC plasma, while HBV-ACLF plasma combined with anti-IL-6 and/or anti-TNF-α resulted in decreased BTLA expression on CD4+ T cells. Data were calculated as mean ± SEM (a, b, d), Kruskal-Wallis H test followed by Dunn’s multiple comparison test (a), Wilcoxon test (c), and one-way ANOVA followed by Tukey’s (b) or Dunnett’s multiple comparison test (d). A two-sided P < 0.05 was considered significant.CC BY · PubMed Central
Fig. 4 Crosslinked BTLA markedly inhibited the activation, production of cytokines, and proliferation of BTLA+CD4+ T cells but promoted apoptosis. a Flow cytometry for CD25, CD38, and CD69 (n = 8 donors), (b) production of IFN-γ, IL-2, and TNF-α induced by phorbol 12-myristate 13-acetate /ionomycin (n = 12 donors), (c, d) proliferation (n = 8 donors), and apoptosis of BTLA+CD4+ T cells from NC (n = 8 donors) in the control and crosslinked anti-BTLA groups. Wilcoxon test (a–d). A two-sided P < 0.05 was considered significant.
Fig. 4 Crosslinked BTLA markedly inhibited the activation, production of cytokines, and proliferation of BTLA+CD4+ T cells but promoted apoptosis. a Flow cytometry for CD25, CD38, and CD69 (n = 8 donors), (b) production of IFN-γ, IL-2, and TNF-α induced by phorbol 12-myristate 13-acetate /ionomycin (n = 12 donors), (c, d) proliferation (n = 8 donors), and apoptosis of BTLA+CD4+ T cells from NC (n = 8 donors) in the control and crosslinked anti-BTLA groups. Wilcoxon test (a–d). A two-sided P < 0.05 was considered significant.CC BY · PubMed Central
Fig. 5 BTLA knockdown increased activation, production of cytokines, and proliferation of CD4+ T cells but abrogated apoptosis. a BTLA expression (left) and MFI (right) in freshly isolated PBMC activated for 3 days in the presence of control shRNA and varying concentrations of BTLA shRNA (n = 5 donors). b Carboxyfluorescein succinimidyl ester (CFSE) indicates the proliferation of the CD4+ T cells that were activated by anti-CD3/CD28 stimulation for 5 days in the presence of control shRNA and BTLA shRNA (left). The quantification (right) is presented as a division index (n = 6 donors). c Contour plots (up) and line graphs (down) display frequencies of Annexin V+CD4+ T cells in the presence of control shRNA and BTLA shRNA (n = 6 donors). d Contour plots (left) and line graphs (right) display frequencies of IFN-γ, IL-2, and TNF-α-expressing cells on CD4+ T cells induced by PMA/ionomycin for 6 h in the presence of control shRNA and BTLA shRNA (n = 6 donors). e Expression of CD25, CD38, and CD69 on CD4+ T cells activated by anti-CD3/CD28 for 1 day in the presence of control shRNA and BTLA shRNA. All PBMC were isolated from NC (n = 6 donors). Data were calculated as mean ± SEM (a), one-way ANOVA followed by Dunnett’s multiple comparison test (a), and Wilcoxon test (b–e). A two-sided P < 0.05 was considered significant.
Fig. 5 BTLA knockdown increased activation, production of cytokines, and proliferation of CD4+ T cells but abrogated apoptosis. a BTLA expression (left) and MFI (right) in freshly isolated PBMC activated for 3 days in the presence of control shRNA and varying concentrations of BTLA shRNA (n = 5 donors). b Carboxyfluorescein succinimidyl ester (CFSE) indicates the proliferation of the CD4+ T cells that were activated by anti-CD3/CD28 stimulation for 5 days in the presence of control shRNA and BTLA shRNA (left). The quantification (right) is presented as a division index (n = 6 donors). c Contour plots (up) and line graphs (down) display frequencies of Annexin V+CD4+ T cells in the presence of control shRNA and BTLA shRNA (n = 6 donors). d Contour plots (left) and line graphs (right) display frequencies of IFN-γ, IL-2, and TNF-α-expressing cells on CD4+ T cells induced by PMA/ionomycin for 6 h in the presence of control shRNA and BTLA shRNA (n = 6 donors). e Expression of CD25, CD38, and CD69 on CD4+ T cells activated by anti-CD3/CD28 for 1 day in the presence of control shRNA and BTLA shRNA. All PBMC were isolated from NC (n = 6 donors). Data were calculated as mean ± SEM (a), one-way ANOVA followed by Dunnett’s multiple comparison test (a), and Wilcoxon test (b–e). A two-sided P < 0.05 was considered significant.CC BY · PubMed Central
Fig. 6 Crosslinking of BTLA phosphorylated the SHP1/2 protein and activated the PI3K-Akt-GSK-3β pathway. a, b Venn diagram (left) and heatmap (right) of DEGs, 237 of which were shared by NC (n = 3 donors), CHB (n = 3 donors) and HBV-ACLF patients (n = 3 donors). c KEGG pathway analysis showed that the PI3K-Akt pathway was significantly different, with the largest DEG in the upregulated signaling pathways. d Crosslinking of BTLA phosphorylates the SHP1/2 protein and activates the PI3K-Akt-GSK-3β pathway in purified CD4+ T cells. Data represent two experiments.
Fig. 6 Crosslinking of BTLA phosphorylated the SHP1/2 protein and activated the PI3K-Akt-GSK-3β pathway. a, b Venn diagram (left) and heatmap (right) of DEGs, 237 of which were shared by NC (n = 3 donors), CHB (n = 3 donors) and HBV-ACLF patients (n = 3 donors). c KEGG pathway analysis showed that the PI3K-Akt pathway was significantly different, with the largest DEG in the upregulated signaling pathways. d Crosslinking of BTLA phosphorylates the SHP1/2 protein and activates the PI3K-Akt-GSK-3β pathway in purified CD4+ T cells. Data represent two experiments.CC BY · PubMed Central
Fig. 7 BTLA expression contributed to immune exhaustion, increased mortality rate, and bacterial burden in the ACLF model induced by ConA. a, b Schematic diagram (left) of ACLF induced by continuous injection of ConA (8 mg/kg) and hematoxylin-eosin diagrams (right) of liver pathology at baseline and days 8 and 14 in WT (n = 10 mice) and BTLA-/- (n = 10 mice) C57BL/6 mice. c BTLA expression on CD4+ T cells was significantly increased on days 8 and 14, compared to baseline, in WT mice (n = 10 mice) following ConA injection. d The percentages and MFI of activation indices (CD25, CD38, and CD69) were higher in BTLA-/- mice (n = 10 mice) than in WT mice (n = 10 mice) following ConA injection on day 14. e The levels of IFN-γ and TNF-α were higher in BTLA-/- mice (n = 10 mice) than in WT mice (n = 10 mice) at days 8 and (or) 14. f The cecal ligation and puncture (CLP) model of sepsis was established based on WT (n = 8 mice) and BTLA-/- ACLF mice (n = 9 mice) induced by continuous ConA injection. g Following CLP, BTLA-/- mice were significantly protected from mortality compared to WT mice. h Bacterial DNA levels in whole blood were significantly decreased in BTLA-/- ACLF mice (n = 9 mice) compared to those in WT mice (n = 8 mice) following CLP. Data were calculated as mean ± SEM (c–e), one-way ANOVA followed by Dunnett’s multiple comparison test (c), Two-way ANOVA followed by Sidak’s multiple-comparison test (d, e), Wilcoxon test (h), log-rank test for survival study (g). A two-sided P < 0.05 was considered significant.
Fig. 7 BTLA expression contributed to immune exhaustion, increased mortality rate, and bacterial burden in the ACLF model induced by ConA. a, b Schematic diagram (left) of ACLF induced by continuous injection of ConA (8 mg/kg) and hematoxylin-eosin diagrams (right) of liver pathology at baseline and days 8 and 14 in WT (n = 10 mice) and BTLA-/- (n = 10 mice) C57BL/6 mice. c BTLA expression on CD4+ T cells was significantly increased on days 8 and 14, compared to baseline, in WT mice (n = 10 mice) following ConA injection. d The percentages and MFI of activation indices (CD25, CD38, and CD69) were higher in BTLA-/- mice (n = 10 mice) than in WT mice (n = 10 mice) following ConA injection on day 14. e The levels of IFN-γ and TNF-α were higher in BTLA-/- mice (n = 10 mice) than in WT mice (n = 10 mice) at days 8 and (or) 14. f The cecal ligation and puncture (CLP) model of sepsis was established based on WT (n = 8 mice) and BTLA-/- ACLF mice (n = 9 mice) induced by continuous ConA injection. g Following CLP, BTLA-/- mice were significantly protected from mortality compared to WT mice. h Bacterial DNA levels in whole blood were significantly decreased in BTLA-/- ACLF mice (n = 9 mice) compared to those in WT mice (n = 8 mice) following CLP. Data were calculated as mean ± SEM (c–e), one-way ANOVA followed by Dunnett’s multiple comparison test (c), Two-way ANOVA followed by Sidak’s multiple-comparison test (d, e), Wilcoxon test (h), log-rank test for survival study (g). A two-sided P < 0.05 was considered significant.CC BY · PubMed Central
Fig. 8 BTLA contributed to immune exhaustion and increased mortality and infection rates in the ACLF model induced by CCl4. a Schematic diagram of ACLF induced by continuous injection of CCl4 (0.2 mL/kg, twice a week) for 8 weeks and subsequent injection of a double dose of CCl4 (0.4 mL/kg). b Hematoxylin-eosin diagram of liver pathology at baseline, 8 weeks, and 8 week + 3 days in WT (n = 10 mice) and BTLA-/- (n = 10 mice) C57BL/6 mice. c Cytokine (TNF-α, IL-2, and IFN-γ) production in CD4+ T cells was higher in BTLA-/- mice (n = 10 mice) than in WT mice (n = 10 mice) at 6 and 8 weeks. d Cytokine (TNF-α, IL-2, and IFN-γ) levels were markedly increased in the plasma of BTLA-/- mice (n = 10 mice) compared to those in WT mice (n = 10 mice) after a double dose of CCl4 injection. e, g Schematic diagram of intraperitoneal (i.p.) K.P. and anti-BTLA antibodies. f, h Survival rate and K.P. load in peripheral blood of both BTLA-/- (n = 10 mice) and WT mice injected with anti-BTLA antibodies (n = 10 mice) were higher than those in the WT (n = 10 mice) and anti-IgG injection groups (n = 9 mice). Data were calculated as mean ± SEM (c, d, f, h), two-way ANOVA followed by Sidak’s multiple-comparison test (c, d), Wilcoxon test (f, h right), log-rank test for survival study (f, h left). A two-sided P < 0.05 was considered significant.
Fig. 8 BTLA contributed to immune exhaustion and increased mortality and infection rates in the ACLF model induced by CCl4. a Schematic diagram of ACLF induced by continuous injection of CCl4 (0.2 mL/kg, twice a week) for 8 weeks and subsequent injection of a double dose of CCl4 (0.4 mL/kg). b Hematoxylin-eosin diagram of liver pathology at baseline, 8 weeks, and 8 week + 3 days in WT (n = 10 mice) and BTLA-/- (n = 10 mice) C57BL/6 mice. c Cytokine (TNF-α, IL-2, and IFN-γ) production in CD4+ T cells was higher in BTLA-/- mice (n = 10 mice) than in WT mice (n = 10 mice) at 6 and 8 weeks. d Cytokine (TNF-α, IL-2, and IFN-γ) levels were markedly increased in the plasma of BTLA-/- mice (n = 10 mice) compared to those in WT mice (n = 10 mice) after a double dose of CCl4 injection. e, g Schematic diagram of intraperitoneal (i.p.) K.P. and anti-BTLA antibodies. f, h Survival rate and K.P. load in peripheral blood of both BTLA-/- (n = 10 mice) and WT mice injected with anti-BTLA antibodies (n = 10 mice) were higher than those in the WT (n = 10 mice) and anti-IgG injection groups (n = 9 mice). Data were calculated as mean ± SEM (c, d, f, h), two-way ANOVA followed by Sidak’s multiple-comparison test (c, d), Wilcoxon test (f, h right), log-rank test for survival study (f, h left). A two-sided P < 0.05 was considered significant.CC BY · PubMed Central

Verification

Claims the paper makes

16 Valid · 1 Not valid · 20 Not checked · 104 Own results and interpretations

80 more claims · 2 with their cited sources checked

Create a free account to see all 141 claims and to verify the 12 references still open.

See all claims — free account
  • Probably not a substantial claim. 24
  • It may state two separate claims as one. 41
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Citations

Cites

Show all 47 references

Research works printed but not linked: 2

  1. Zhang N Establishment of model of dynamic change of immune status of ACLF induced by ConA repeated administration in mice. Chin. J. Gastroenterol. 2016 21 326 330
  2. Mann P. C. International Specification for Terminology and Diagnostic Criteria for Pathological Changes in Rats and Mice (INHAND) (Beijing: China Agriculture Press, 2019).

Cited by

See all 47

Metadata

Authors
Yu, X., Yang, F., Shen, Z., Zhang, Y., Sun, J., Qiu, C., Zheng, Y., Zhao, W., Yuan, S., Zeng, D., Zhang, S., Long, J., Zhu, M., Zhang, X., Wu, J., Ma, Z., Zhu, H., Su, M., Xu, J., Li, B., Mao, R., Su, Z., & Zhang, J.
Affiliations
  • Fujian Medical University (CN)
  • Fudan University (CN)
  • Dali University (CN)
  • Shanghai Medical College of Fudan University (CN)
  • Shanghai Jiao Tong University (CN)
Corresponding author
  • Yu, Xueping
  • Mao, Richeng
  • Su, Zhijun
  • Zhang, Jiming
Venue
Nature Communications
Published
2024-02-28
Volume
15
Issue
1
Pages
1835-1835
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4392231520
Cited by
47
References
48
Citations by year
2026: 23 · 2025: 22 · 2024: 2
FWCI
14.25
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Greater South Information System
Funders
  • National Natural Science Foundation of China (82370604, 82372237, ZD2021CY001, 82160361, 2017ZX10202203-007, 81670528, 82003864, 2017ZX10202203, 2017ZX10202202)
  • Natural Science Foundation of Fujian Province (2023J01239, 2019J01593)
Topics
  • Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
BTLA, acute-on-chronic liver failure, hepatitis B virus, CD4+ T cell exhaustion, infection susceptibility, Klebsiella pneumoniae, bacterial infection, IL-6 signaling, TNF signaling, PI3K/Akt signaling, T cell apoptosis
MeSH terms
T-Cell Exhaustion, Animals, Humans, Receptors, Immunologic, CD4-Positive T-Lymphocytes, Cytokines, Hepatitis B, Chronic, Phosphatidylinositol 3-Kinases, Mice, Acute-On-Chronic Liver Failure

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion. https://app.cochat.ai/papers/10.1038/s41467-024-46047-8
The paper
Yu, X., Yang, F., Shen, Z., Zhang, Y., Sun, J., Qiu, C., Zheng, Y., Zhao, W., Yuan, S., Zeng, D., Zhang, S., Long, J., Zhu, M., Zhang, X., Wu, J., Ma, Z., Zhu, H., Su, M., Xu, J., . . . Zhang, J. (2024). BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion. Nature Communications. https://doi.org/10.1038/s41467-024-46047-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.